anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to natural seaweed gel-containing multifunctional shower gel. Effective components of the shower gel comprise natural seaweed gel, quillaja saponin, natural betaine, Fenglian anthocyanin, frankincense essence, geranium essential oil and citric acid. The shower gel is used for daily skin care which includes cleaning, moisturizing and antioxidation. Bath products have become the most important cleaning products since hygiene and skin care have been paid more and more attention to. The shower gel as an emulsion-like bath product adopts pure natural plant extracts without any chemical components and utilizes natural seaweed gel as a mask matrix replacing chemical emulsifier and mineral oil on the market. The shower gel uses pure plant extracts as a surfactants and adopts specially plant-derived natural antibacterial agents as preservatives to reduce skin irritation. In addition, the shower gel uses natural citric acid as pH regular to adjust the pH so that the shower gel is weakly acidic and is suitable for the skin. The shower gel has the characteristics of skin protection, moderate cleaning effect, efficient moisturizing and antioxidation, skin metabolism promotion, no toxicity, no irritation and environmental friendliness.
Deaths may occur from overdosage with this class of drugs. Overdose of desipramine has resulted in a higher death rate compared to overdoses of other tricyclic antidepressants. Multiple drug ingestion (including alcohol) is common in deliberate tricyclic antidepressant overdose. As the management is complex and changing, it is recommended that the physician contact a poison control center for current information on treatment. Signs and symptoms of toxicity develop rapidly after tricyclic antidepressant overdose; therefore, hospital monitoring is required as soon as possible. There is no specific antidote for desipramine overdosage.
Primiparous pregnant women who come to the pregnancy outpatient clinic, are at 36 weeks of gestation or more, meet the inclusion criteria and volunteer, will be informed about the program and will be included in the sample of the study. There will be two groups assigned by the stratified block randomization method in the study. The number of samples to be taken into the control and intervention groups was determined by power analysis and the sample size was planned to be 32 mothers for the intervention group and 32 mothers for the control group. In addition to routine hospital care, the intervention group will receive navigation program-based nursing care that includes three home visits, three phone calls, and sending text messages at five different times. The control group will not receive any intervention other than routine hospital care practices. The data of the research; "Data Collection Form on Descriptive Characteristics", "Postpartum Mother and Newborn Evaluation and Diagnosis Form", "Mother and Newborn Problems Evaluation Form in the Postpartum Period", "Mother and Baby Follow-up Evaluation Form in the Postpartum Period", "Self-Care Power" Scale', 'Postpartum Quality of Life Scale', 'Postpartum Specific Anxiety Scale', 'Edinburgh Postpartum Depression Scale' and 'Physical Symptom Severity Scale' will be collected using descriptive statistics (number, min., mean, standard deviation, standard deviation) in the evaluation of the data. max.) will be used. The conformity of the data to the normal distribution will be evaluated with the Shapiro Wilks test. The relationship between them in qualitative variables will be evaluated with the chi-square test and Fisher's exact test. The Cochran Q test will be used to examine change over time. In numerical variables, according to the normal distribution; In independent groups, t test, Mann Whitney U test, one-way analysis of variance (ANOVA), Kruskal Wallis Analysis will be used. Before and after repeated measurements, according to the normal distribution; In repeated measurements, one-way analysis of variance or Friedman test will be used. Significance will be evaluated at the p\<0.05 level. The independent variables of the research will be stated as numbers and percentages.
Many patients with SCI are ambulatory with a wheelchair. Therefore, providing good sitting balance in these patients is a key factor for performing activities of daily living (ADL) and achieving functional independence. Paralysis of abdominal muscles in patients with SCI disrupts body balance. In these patients, problems with trunk balance can lead to frequent falls and poor rehabilitation outcomes. Also, abdominal muscles assist in forceful expiration. Loss of innervation to abdominal and intercostal muscles reduces their ability to excrete secretions and cough effectively. As a result, respiratory tract complications, such as pneumonia, atelectasis, and respiratory failure can arise. It should be noted that in individuals with SCI, respiratory tract complications are the primary cause of morbidity and mortality. Newly used SiFES is a method in which the biofeedback-enabled FES device detects muscle contractions, and this electromyography (EMG) signal triggers the muscle stimulant mode of the device. In this method, more stimuli are conveyed to the brain through afferent nerves, allowing for motor learning to potentially occur by reviving the region represented in the cortex. In the current study, the investigators planned due to the anticipation that the synchronized stimulation of SiFES with function will be effective in patients with SCI injuries who currently have weak contraction abilities. The investigators considering the key role of abdominal muscles in trunk stability, believed that the integrated effect of SiFES is of great importance to patients. In the current randomized controlled and prospective study, the investigators included thirty-four participants with thoracic complete SCI. The investigators divided the participants into two equal groups: one group received SiFES applied to the abdominal muscles, while the control group received therapeutic exercise (TE) only. The investigators administered the interventions three times a week for four weeks. The investigators conducted muscle thickness measurements of bilateral rectus abdominis (RA), obliques externus (OE), obliques internus (OI), and transversus abdominis (TA) muscles using ultrasonography for all participants before and after treatment. Additionally, the investigators applied the modified functional reach test (mFRT), trunk control test (TCT), and pulmonary function test (PFT) to assess the participants.
The present invention discloses an eocarpium citri grandis phlegm reducing black rice cake and production method thereof. The black rice cake contains the following raw materials in parts by weight: 100-120 parts of black glutinous rice, 30-40 parts of glutinous rice, 30-40 parts of panicum miliaceum, 10-20 parts of wheat starch, 10-15 parts of coconut powder, 8-10 parts of traditional Chinese medicine powder, 2-4 parts of spice powder, and 2-4 parts of five-flower sauce. The traditional Chinese medicine powder is prepared from eocarpium citri grandis, radix isatidis, fructus cannabis, sievers wormwood herbs, cortex magnoliae officinalis, corn stigma, bulbus allii macrostemonis, semen alpiniae katsumadai, furnace soil, radix et rhizoma rhei, peach kernels, and loquat leaves. The main steps of the production method are as follows: grinding, Chinese traditional medicinal powder preparing, spice powder preparing, five-flower sauce preparing, mixing, steaming, and shaping. The eocarpium citri grandis phlegm reducing black rice cake is prepared from purely natural raw materials. A combination of a Chinese herbal medicine formula and the rice cake is very important. The delicious rice cake is pleasant for people to eat, the physical symptoms of people can be effectively improved and the medicines are reasonably and effectively combined. The rice cake can be eaten for a long period of time and has the efficacies of reducing phlegm, regulating qi, and strengthening stomach.
Enroll 60 eyes with posttrabeculectomy glaucoma (30 eyes with posttrabeculectomy residual primary angle-closure glaucoma. 30 eyes with posttrabeculectomy residual primary open angle glaucoma). Inclusive at 9 AM at eligibility visit and previously undergone trabeculectomy at least 30 days before screening visit. Qualified patients had a mean intraocular pressure (IOP) between 21 and 35mm Hg. All patients had documented residual PACG/POAG after trabeculectomy, with inadequate IOP control in at least one eye.The right eye was selected if both eyes showed about the same IOP. The previous IOP-lowering drugs were washed out before using tafluprost. Because all of the eyes had critical IOP levels, the design of this study was open-label, with emphasis on IOP change. Both patients in PACG and POAG groups will dose 1 time daily in each eye for 6 months. Each eye will be preformed tafluprost 0.0015% at 9 PM.The investigator monitored compliance via review of bottles at each follow-up visit, and at the last visit the old bottles will be returned and the investigator will keep them for storage. Efficacy and safety evaluations will be conducted at months 1, 2, 3, 4, 5, and 6 after the start of tafluprost treatment.The IOP will be measured at 1, 2, 3, 4, 5, and 6 month visit. All IOP measurements are to be performed at about the same time of day (at 9 AM at each visit). IOP was measured by Goldmann tonometer. The IOP value was the mean of 3 consecutive measurements.A visual field examination with automated perimetry(Octopus 101) using a threshold program was performed at the screening visit. If the visual field examination has been carried out within 12 weeks before the screening visit, no additional visual filed examination is required at the screening visit. A visual field examination and RNFL(retina nerve fiber layer) examination are to be performed at screening and the last visit respectively by the same technician with the same protocol. Topical examination by slit lamp is to be performed to evaluate the anterior segment. Ophthalmoscope examinations will be performed at screening and the last visit to examine the vitreous body, retina, and optic nervehead.The efficacy of tafluprost therapy is to be evaluated by comparing the baseline IOP and the IOP at various intervals after the start of treatment, by ANOVA test. The comparison of two groups was estimated by t test. The difference of the time point IOP between the 2 groups was analyzed by X2 test.
Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) will be conducted in accordance with the Cognitive Behavioral Therapy for Chronic Pain: Therapist Manual and the VA Evidence-Based Practice (EBP) roll-out training. CBT-CP consists of a 12-session protocol, including an initial assessment session (BL assessment; Session 1), 10 content-specific sessions (pain education, goal-setting, cognitive and behavioral skill building; Sessions 2-11), and a booster session scheduled approximately one month after the final CBT-CP session (Session 12). Participants randomized to the CBT-CP condition (n = 30) will complete one 60-minute individual session per week. Each CBT-CP session will be led by a trained study interventionist using a manualized curriculum, following a basic structure including review of previous session material, introduction of new information or skills, and discussion of how to implement learned material into a home action plan.
At present, the third generation of platinum-based regimens (NCCN clinical practice guidelines recommended the use of vinorelbine or gemcitabine, or Taxol, etc.) is the first-line treatment for advanced lung cancer patients. Its effective rate is 20-30%, the median survival time is 7-9 months, 1-year and 2-year survival rate is 31-36% and 10-13% respectively. The efficacy has reached the platform and it is difficult to have more breakthroughs. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as Iressa and Erlotinib have proved effective in first or second line therapy for advanced non-small cell lung cancer(NSCLC).First-SIGNAL and IPASS research have laid first-line status for gefitinib in treatment of NSCLC and the progression-free survival time was maintained at 9-10 months. EGFR-TKIs treatment is simple, well tolerated, drug side effects, etc. There are also a rash, diarrhea and other adverse reactions, affecting the quality of life of patients with serious or even give patients a great deal of pain.Literature and our preliminary studies have shown that traditional Chinese medicine (TCM) can prolong survival time and improve quality of life QOL, but high-level evidences are needed.

The investigators perform a randomized, double-blind controlled, prospective study in Advanced Pulmonary Adenocarcinoma patients with stage Ⅲa～Ⅳ. Patients are randomized over observational group (TCM granules plus first-line targeted therapy and TCM granules plus second-line targeted therapy ), and control group (TCM placebo plus first-line targeted therapy and TCM placebo plus second-line targeted therapy). The investigators will observe 6 months and after that regular follow-up will be arranged. The primary efficacy assessments are: PFS (progression-free survival）; Secondary efficacy assessments are: (1) OS(overall survival); (2) Objective response rate; (3) TTP（Time-to-Progression）; (4) QOL (Functional Assessment of Cancertherapy-lung, FACT-L4.0 scales;Lung Cancer Symptom Scale,LCSS); (5)other efficacy assessments are: 1) TCM symptoms changes; 2) Toxicity, side effects and security of the treatments will be assessed at the same time. The investigators expect that integrated TCM combined with targeted therapy has a better efficacy on prolonging progression-free survival time, overall survival, improving QOL of patients than that of targeted therapy. Therefore our study can provide evidences for optimizing and promoting integrated TCM combined with Western Medicine treatment.
Patients with chronic kidney disease (CKD) suffer disproportionately from a high burden of cardiovascular disease, which, despite recent scientific advances, remains partly understood. Vascular calcification (VC) is the result of an ongoing process of misplaced calcium in the inner and medial layers of the arteries, which has emerged as a critical contributor to cardiovascular events in CKD. Beyond its established role in blood clotting and bone health, vitamin K appears crucial in regulating VC via vitamin K-dependent proteins (VKDPs). Among these, the matrix Gla protein (MGP) serves as both a potent inhibitor of VC and a valuable biomarker (in its inactive form) for reflecting circulating vitamin K levels. CKD patients, especially in advanced stages, often present with vitamin K deficiency due to dietary restrictions, medications, and impaired intestinal absorption in the uremic environment. Epidemiological studies confirm a strong association between vitamin K levels, inactive MGP, and increased CVD risk across CKD stages. Based on the promising results of pre-clinical data, an increasing number of clinical trials have investigated the potential benefits of vitamin K supplementation to prevent, delay, or even reverse VC, but the results have remained inconsistent.
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention relates to derivatives of 4-mercaptobenzoylguanidine of the formula (I)   where R 1  means A; R 2  means A, unsubstituted phenyl or phenyl substituted with F, Cl, Br, pyridyl; A is alkyl with 1-6 C-atoms and their physiologically acceptable salts, method of their synthesis and pharmaceutical composition based on thereof. Proposed compounds and pharmaceutical composition inhibit Na + /H + -antiporter and therefore prevent cardiac disease and show cardioprotective effect. They can be used for treatment and prophylaxis of patients with arrhythmia, stenocardia, infarct and pathological hypoxic and ischemic damages. EFFECT: improved method of synthesis, valuable medicinal properties. 4 cl, 1 tbl, 4 ex
Lunch ad libitum on test day 1 and no lunch on test day 2. Water available on both days.
Patients receive orteronel 300 mg PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Histidine is an essential amino acid with health benefits that include anti-inflammatory, anti-oxidant, glucoregulatory, and weight management. Because of the extended period of time (\>35 days) that is required to deplete body histidine pools in adults, it has not been possible to fully determine histidine requirements. The current expert opinion for histidine intake is 8 and 12 mg/(kg body weight per day), an estimate that was extrapolated from the infant requirement for histidine. The average intake of histidine from a normal adult diet in the U.S., Europe, and Japan was reported between 2.12 and 2.40 g/day with the 99th percentile intake in men at 50-70 years of age consuming 5.20 g/day. The clinical safety of histidine supplementation above the average dietary intake has not been determined. Therefore, this study will utilize graded doses of histidine that are at are moderately above the average intake to identify safety and benefits of histidine in a healthy human population. Further, the clinical safety of histidine supplementation above the average dietary intake has not been determined.The overarching objectives are to 1) measure the safety of histidine supplementation and 2) measure the potential benefits of histidine at doses above the average intake and current recommendation in a healthy adult population. Following the completion and review of a health history questionnaire, vitals, and a biochemical panel, participants will be deemed healthy by a nurse practitioner and able to participate. After baseline measures are obtained, supplements (encapsulated histidine) will be provided at three graded doses (4 g/day, 8 g/day and 12 g/day) a forth dose (16 g/day) will be consumed if no adverse effects are observed at the three graded doses. Each dose will be for 28 days followed by a three week recovery period. At baseline, weeks 2 and 4 of supplement, and recovery a basic biochemical panel, anthropometric, urinary and serum zinc, will be conducted. Additionally, body composition will be conducted at baseline and week 4 of each dose. Changes in dietary intake and physical activity will be measured with 4-day food records and Actigraph activity monitors, respectively. Changes in sleep patterns will be measured with the Pittsburgh sleep questionnaire.
Those randomized to the study arm will receive a dose of IVIG 1 gram/kg at 12 hours post-cardiopulmonary bypass. This is a one time only dose and will be administered per hospital standards for IVIG administration.
The present invention provides a peptide comprising 1) a B-cell epitope, 2) a protective part, and 3) a Th epitope. The B-cell epitope and the protective part combine to form a Th-epitope-protective epitope. The peptide is characterized in that the protective part is linked to the N'-terminus and C'-terminus of the Th epitope, and when injected into a body of a subject, an antibody that specifically binds to an intentionally designed B-cell epitope is uniformly induced. In addition, since the peptide contains a small number of B-cell and Th epitopes, the prsesent invention has advantages of easy production and economical efficiency. The peptide may be used as an immunotherapeutic agent according to its characteristics. Accordingly, a peptide designed to be used as an immunotherapeutic agent for obesity and a pharmaceutical composition thereof are provided.
The invention discloses a preparation method of Azelnidipine of alpha crystal form, wherein, Azelnidipine of non-alpha crystal forms is completely dissolved in a two-phase organic solvent. Water-bath is heated to certain temperature and alkane and seed crystal are added into the solution under a stirring condition. A crystal is separated out by cooling and a separated crystal product is collected, namely the Azelnidipine of alpha crystal form. The two-phase organic solvent comprises two components: low boiling point esters and benzene or derivatives of benzene, with a volume ratio of 1 to 3:15. The preparation method has one-time yield up to 85 percent to 90 percent, purity of more than 99.5 percent as well as good appearance and quality. The preparation method has easily recycled organic solvent, is beneficial to environmental protection, reduces loss in Azelnidipine and/or waste in the organic solvent, greatly reduces the production costs of products and has prospect of large-scale industrialized production.
PURPOSE: A platelet activation method by applying capillary tube stress is provided to rapidly and efficiently activate platelet by using relatively simple device. CONSTITUTION: A platelet activation method by applying capillary tube stress includes a step of applying capillary tube stress to biological fluid which includes platelets. The capillary tube stress application is processed by passing the biological fluid through a path having the inner diameter of 2 mm or less. The inner wall of the path has concave convex form. The path has curve. The inner diameter of the path is variable. The path is needle. The path is a micro fluidic device having micro channels. The biological fluid is blood, plasma, PRP(platelet rich plasma), PPP(platelet poor plasma) or a platelet - inclusion solution. The path has the positive charge or negative charge on the inner wall.
Subjects randomized to DMT arm in a 1:1 ratio. A loading dose of 1 mcg/kg will be given followed by 0.1 to 0.5 mcg/kg/h continuous infusion. The Neonatal Pain, Agitation, and Sedation Scale (N-PASS) will be used to determine infusion rate.
JNJ-73763989 (JNJ-3989) is a liver-targeted antiviral therapeutic for subcutaneous injection designed to treat chronic hepatitis B virus (HBV) infection via a ribonucleic acid interference (RNAi) mechanism. Combination treatment with JNJ-73763989 and NA has the potential to specifically decrease HBV viral antigen levels and inhibit viral replication. Since HBsAg is immune suppressive, the direct reduction of HBsAg levels by JNJ-73763989 is anticipated to contribute to the restoration of the immune response that is impaired in chronic HBV infection. Pegylated interferon (PegIFN) is an approved drug for the treatment of chronic HBV infection and after a finite treatment duration of 48 weeks results in slightly increased HBsAg seroclearance rates. The primary hypothesis of this study is that at least one of the combination regimens of JNJ-73763989+NA+PegIFN-alpha-2a is more efficacious than NA treatment alone (standard of care), as measured by the primary efficacy endpoint. This study will be conducted in 3 periods: Screening Period (4 weeks), Treatment Period (24 weeks) and Follow-up (FU) Period (48 weeks), starting at Week 24. Safety assessments will include adverse events (AEs), serious AEs, clinical safety laboratory tests, electrocardiograms (ECGs), vital signs, ophthalmologic examinations and physical examinations. Total duration of individual participation will be up to 76 weeks (including screening period).